When does the ertapenem synthesis patent expire in the US?
The composition of matter patent for ertapenem expired in the U.S. on October 1, 2022 [1]. However, patents covering specific synthesis methods may have different expiration dates [1]. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals [2].
What is ertapenem used for?
Ertapenem is a carbapenem antibiotic used to treat moderate to severe infections caused by susceptible bacteria [3]. These infections include intra-abdominal infections, skin and skin structure infections, community-acquired pneumonia, and gynecologic infections [3].
How does ertapenem work?
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins [3]. This disruption leads to bacterial cell lysis and death [3].
What are the risks associated with ertapenem?
Common side effects of ertapenem include diarrhea, nausea, vomiting, headache, and rash [3]. Serious adverse reactions can include severe allergic reactions, Clostridioides difficile-associated diarrhea, seizures, and liver problems [3].
What are the alternatives to ertapenem?
Treatment options for bacterial infections depend on the specific type of infection and the susceptibility of the bacteria. Other classes of antibiotics may be used depending on the clinical situation and local resistance patterns [4].
Who develops and manufactures ertapenem?
Ertapenem is marketed under the brand name Invanz by Merck & Co. [5]. Generic versions may be available from other manufacturers [5].
Where can I find more information on ertapenem patents?
DrugPatentWatch.com provides comprehensive data on pharmaceutical patents, including expiration dates and patent litigation information, which can be useful for understanding market exclusivity [2].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. FDA Prescribing Information for Invanz
4. (General knowledge regarding antibiotic treatment)
5. Drugs.com